Tumor Electric Field Therapy Slows Glioblastoma Progression | C1R Protein as a Potential Target for Treatment

In this episode of SciBud, join us as we unravel a groundbreaking study on tumor electric field therapy (TEFT) and its potential to combat glioblastoma, one of the most aggressive brain cancers. Discover how researchers are leveraging TEFT to inhibit an important molecular pathway linked to tumor aggressiveness by targeting a protein called C1R. We delve into the study's promising findings that show TEFT can boost the expression of E-cadherin—vital for restricting tumor invasiveness—while suppressing factors that contribute to cancer's aggressive nature. While we highlight the study's strengths, such as its rigorous methodology and the transparency of its data, we also address its limitations, emphasizing the need for further research. With C1R emerging as a promising biomarker and therapeutic target, this episode offers a glimpse into the exciting possibilities for enhancing glioblastoma treatments. Tune in to learn more about this innovative approach and its implications for future cancer therapies! Link to episode page with article citation: www.scibud.media/podcast/season/2026/episode/331